Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
12/2005
12/07/2005EP1117426B1 Akt compositions for enhancing survival of cardiomyocytes
12/07/2005CN1705654A Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram
12/07/2005CN1230202C External coated chewing gum products
12/07/2005CN1230174C Selective iGLuR5 receptor antagonists for the treatment of migraine
12/07/2005CN1230172C Blood circulation improving agent
12/06/2005US6972321 Monomeric protein of the TGF-β family
12/06/2005US6972299 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
12/01/2005US20050267205 2,4-dihydroxybenzoic acid derivatives
12/01/2005US20050267190 Solid-state form of celecoxib having enhanced bioavailability
12/01/2005US20050267189 Celecoxib compositions
12/01/2005US20050267186 Minimal cardivascular and/or sedatory activity; treating pain and allodynia; selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors;
12/01/2005US20050267129 Dipeptide nitrile cathepsin K inhibitors
12/01/2005US20050267044 Novel compounds and compositions as cathepsin S inhibitors
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer
12/01/2005US20050266002 Methods for the treatment of cancer using anti-CD40 antibodies
12/01/2005US20050265976 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells
11/2005
11/30/2005EP1600445A1 Medicinal composition
11/30/2005EP1600180A2 Antiproliferative drug and delivery device
11/30/2005EP1600166A1 Skeletal muscle protecting agent
11/30/2005EP1600163A1 Use of the neurotoxic component of botulinum toxins for the treatment of spastic muscle
11/30/2005EP1599482A1 Pyrazolo 1,5-a pyrimidine derivatives
11/30/2005EP1599218A1 Clostridial neurotoxins for treating uterine disorders
11/30/2005EP1221941A4 Powder pharmaceutical formulations
11/30/2005EP1185306B1 Use of viral vectors and charged molecules for gene therapy
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005CN1703405A Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors
11/30/2005CN1703197A Injectable depot compositions and uses thereof
11/30/2005CN1229381C Macrolides compound
11/30/2005CN1229375C Nicotinic acetylcholine receptor inhibitor, its prepn. and application
11/30/2005CN1229345C N-(indolcarbonyl) piperazin derivatives
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229335C Nervinolin derivatives
11/30/2005CN1229113C A Pharmaceutical composition for the treatment of autoimmune diseases
11/29/2005US6969770 reacting an alpha-keto carboxy acid ester or derivative with a pyrrolidinone to form an intermediate, subjecting the intermediate to asymmetric hydrogenation using a chiral catalyst to form the end product
11/29/2005US6969729 An indole or benz(g)indole-2,3-dione-3-oxime compounds; therapeutic treatment of respiratory disorders, urogenital disorders, cardiovascular disorders, brain and psychological disorders, gastrointestinal disorders
11/29/2005US6969728 Antiinflammatory agents
11/29/2005US6969727 Obesity; osteoporosis
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969707 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
11/24/2005US20050261339 Jun N-terminal kinase inhibitors; neurodegenerative diseases; Alzheimer's disease; amyotrophic lateral sclerosis; multiple sclerosis; spinocerebellar ataxia
11/24/2005US20050261305 Cyclic protein tyrosine kinase inhibitors
11/24/2005US20050261281 Pharmaceutical compounds
11/24/2005US20050261269 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
11/24/2005US20050261231 Improving tissue survival; methods for enhancing organ transplant, musculocutaneous flap or skin graft survival by administering a nucleic acid sequence encoding hepatocyte growth factor; neovascularization; surgery; tissue-targeted therapy
11/24/2005US20050261186 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/24/2005US20050260767 Treatment with cytokines
11/24/2005US20050260601 Recombinant mutants of rhabdovirus and methods of use thereof
11/24/2005US20050260230 Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins
11/24/2005US20050260174 Systems and methods for treating patients with processed lipoaspirate cells
11/24/2005CA2567223A1 Treatment of diseases associated with altered level of amyloid beta peptides
11/24/2005CA2508065A1 Antiproliferative drug and delivery device
11/24/2005CA2507712A1 Pharmaceutical compounds
11/24/2005CA2507710A1 Tricyclic pyrazole derivatives and their use as cb1 or cb2 modulators
11/23/2005EP1598340A1 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598339A1 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598338A1 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598077A1 Use of the neurotoxic component of botulinum toxins for the treatment of a spastic muscle
11/23/2005EP1446015A4 Remodeling of tissues and organs
11/23/2005EP1280777B1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1700934A Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
11/22/2005US6967094 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005107737A1 Antifatigue composition
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256201 Phenethanolamine derivatives
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255113 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
11/17/2005CA2566083A1 Antifatigue composition
11/16/2005EP1594523A2 Pharmaceutical botulinum toxin compositions
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP0904099B1 Pharmaceutical formulation containing human growth hormone, histidine and a non-ionic detergent
11/16/2005EP0876395B1 Inhibitors of interleukin-1beta converting enzyme
11/16/2005CN1697830A 嘧啶衍生物 Pyrimidine derivatives
11/16/2005CN1697828A New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/16/2005CN1227233C 5-chloro-3-(4-methane sulfonylphenyl)-6-methyl-[2,3'] bipyridine and process for synthesis
11/15/2005US6965018 Antibodies directed to B7-related polypeptide, BSL-2
11/15/2005US6964984 Preventing desensitization of receptors
11/15/2005US6964978 Dissolving with crystal growth inihibitos; drying
11/15/2005US6964972 8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors
11/15/2005US6964965 Corticotropin releasing factor antagonists
11/15/2005US6964960 Indoloquinazolinones
11/15/2005US6964956 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization
11/10/2005WO2005106459A1 Method of determining ability of drug to bind to troponin i and test drug for the determination
11/10/2005WO2005105996A1 A pax-encoding vector and use thereof
11/10/2005WO2005105793A1 Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
11/10/2005US20050250936 Modified TGF-beta superfamily proteins
11/10/2005US20050250850 Amino acid composition promoting collagen synthesis
11/10/2005US20050250698 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
11/10/2005US20050250697 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
11/10/2005CA2565024A1 Therapeutic agent for left ventricular diastolic dysfunction
11/09/2005EP1593689A2 Myostatin and mimetics thereof
11/09/2005EP1593683A2 Dihydro-2,3-Benzodiazepine derivatives
11/09/2005EP1593379A2 Uses of PPAR-gamma agonists in neutrophil-induced diseases
11/09/2005EP1511726B1 Method for preparing 1,3,5-triaminobenzene and hydrolyzing it into high-purity phloroglucinol
11/09/2005EP1501787B1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists
1 ... 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 ... 233